Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tonix Pharmaceuticals HoldingTNXP +5.02%39 PB Ratio is 0.73 as of Jul. 15, 2026, which is 11% above its 10-year median of 0.66. GuruFocus rates TNXP with a GF Score™ of 39/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, Tonix Pharmaceuticals Holding ranks better than 90.31% on this metric.
Tonix Pharmaceuticals Holding Corp stock PB Ratio (=0.69) is close to 1-year low of 0.67.
The historical rank and industry rank for Tonix Pharmaceuticals Holding's PB Ratio or its related term are showing as below:
TNXP'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.66 Max: 2.31
Current: 0.73
During the past 13 years, Tonix Pharmaceuticals Holding's highest PB Ratio was 2.31. The lowest was 0.01. And the median was 0.66.
TNXP's PB Ratio is ranked better than 90.31% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs TNXP: 0.73
During the past 12 months, Tonix Pharmaceuticals Holding's average Book Value Per Share Growth Rate was -39.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -92.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Tonix Pharmaceuticals Holding was -92.80% per year. The lowest was -94.70% per year. And the median was -93.75% per year.
Back to Basics: PB Ratio
Tonix Pharmaceuticals Holding (NAS:TNXP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tonix Pharmaceuticals Holding PB Ratio Related Terms
Tonix Pharmaceuticals Holding PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tonix Pharmaceuticals Holding PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's PB Ratio distribution charts can be found below:
* The bar in red indicates where Tonix Pharmaceuticals Holding's PB Ratio falls into.
Tonix Pharmaceuticals Holding PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tonix Pharmaceuticals Holding (TNXP) has a PB Ratio of 0.73 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tonix Pharmaceuticals Holding and its competitors. This is 11% above median its historical median of 0.66. Over the past decade, Tonix Pharmaceuticals Holding's PB Ratio has ranged from 0.01 to 2.31. According to the industry distribution chart, Tonix Pharmaceuticals Holding ranks #119 out of 1228 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Tonix Pharmaceuticals Holding's PB Ratio too high?
Tonix Pharmaceuticals Holding's current PB Ratio of 0.73 is 11% above median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.31. The Biotechnology industry median PB Ratio is 2.90. Tonix Pharmaceuticals Holding's value of 0.73 is 74.8% below this industry median. Based on the distribution chart, Tonix Pharmaceuticals Holding ranks #119 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's PB Ratio compare to ALEC and IMUX?
According to the Biotechnology industry distribution chart, Tonix Pharmaceuticals Holding ranks #119 out of 1228 companies for PB Ratio. This places Tonix Pharmaceuticals Holding in the top 10% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.90. Tonix Pharmaceuticals Holding's value of 0.73 is 74.8% below this benchmark. Historically, Tonix Pharmaceuticals Holding's own PB Ratio has ranged from 0.01 to 2.31 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 2.90, Tonix Pharmaceuticals Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tonix Pharmaceuticals Holding's current PB Ratio of 0.73 is 74.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tonix Pharmaceuticals Holding and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tonix Pharmaceuticals Holding's current PB Ratio is 0.73, which is 11% above median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $11.61 — trading 563.4% above its estimated fair value. The current PB Ratio is 0.73, which is 11% above median its 10-year median of 0.66 and 74.8% below the Biotechnology industry median of 2.90. Tonix Pharmaceuticals Holding's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current PB Ratio is 0.73 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued.
The current stock price of $11.61 is trading 563.4% above its estimated GF Value™ of $1.75.
GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.
Key valuation signals for TNXP:
PB Ratio: 0.73 (11% above median its 10-year median of 0.66)
GF Value™: $1.75 vs. price of $11.61 (563.4% above fair value)
Industry Position: 74.8% below the Biotechnology median (#119 of 1228)
No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tonix Pharmaceuticals Holding Business Description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
39GF Score
Get the complete analysis for TNXP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNXP has been successfully added to your 
